SG11202006990TA - Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent - Google Patents

Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent

Info

Publication number
SG11202006990TA
SG11202006990TA SG11202006990TA SG11202006990TA SG11202006990TA SG 11202006990T A SG11202006990T A SG 11202006990TA SG 11202006990T A SG11202006990T A SG 11202006990TA SG 11202006990T A SG11202006990T A SG 11202006990TA SG 11202006990T A SG11202006990T A SG 11202006990TA
Authority
SG
Singapore
Prior art keywords
plinabulin
administration
composition
induced neutropenia
reducing chemotherapy
Prior art date
Application number
SG11202006990TA
Other languages
English (en)
Inventor
Ramon Mohanlal
Lan Huang
George Lloyd
Original Assignee
Beyondspring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beyondspring Pharmaceuticals Inc filed Critical Beyondspring Pharmaceuticals Inc
Publication of SG11202006990TA publication Critical patent/SG11202006990TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11202006990TA 2018-02-01 2019-01-30 Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent SG11202006990TA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862625290P 2018-02-01 2018-02-01
US201862713486P 2018-08-01 2018-08-01
US201862749060P 2018-10-22 2018-10-22
US201862757648P 2018-11-08 2018-11-08
PCT/US2019/015867 WO2019152530A1 (en) 2018-02-01 2019-01-30 Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent

Publications (1)

Publication Number Publication Date
SG11202006990TA true SG11202006990TA (en) 2020-08-28

Family

ID=67479904

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006990TA SG11202006990TA (en) 2018-02-01 2019-01-30 Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent

Country Status (11)

Country Link
US (1) US20210030843A1 (ko)
EP (1) EP3746076A4 (ko)
JP (2) JP2021512121A (ko)
KR (1) KR20200116477A (ko)
CN (1) CN112105363A (ko)
AU (1) AU2019216305A1 (ko)
BR (1) BR112020015758A2 (ko)
CA (1) CA3089391A1 (ko)
IL (1) IL276197A (ko)
SG (1) SG11202006990TA (ko)
WO (1) WO2019152530A1 (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3265090A4 (en) 2015-03-06 2018-08-01 Beyondspring Pharmaceuticals Inc. Method of treating cancer associated with a ras mutation
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
MY192703A (en) 2016-02-08 2022-09-02 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
MX2018015100A (es) 2016-06-06 2019-09-04 Beyondspring Pharmaceuticals Inc Composicion y metodo para reducir la neutropenia.
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド チューブリン結合化合物およびその治療的使用
WO2018144764A1 (en) 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
JP2022552011A (ja) * 2019-10-15 2022-12-14 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド 鉄障害を処置するための方法及び組成物
JP2023505506A (ja) * 2019-12-05 2023-02-09 ハンミ ファーマシューティカルズ カンパニー リミテッド 化学療法または放射線療法で誘導された好中球減少症を治療する方法
CA3186416A1 (en) * 2020-07-17 2022-01-20 John A. Barrett Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complex
WO2022133492A1 (en) * 2020-12-18 2022-06-23 Beyondspring Pharmaceuticals, Inc. Compositions and methods for generating anti-tumor immune response
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012515222A (ja) * 2009-01-16 2012-07-05 テバ ファーマシューティカル インダストリーズ リミテッド 組換えヒトアルブミン−ヒト顆粒球コロニー刺激因子融合タンパク質の安定な製剤
MX2016004441A (es) * 2013-10-11 2016-10-28 Beyondspring Inc Tratamiento del cancer con una combinacion de plinabulina y taxano.
MX2018015100A (es) * 2016-06-06 2019-09-04 Beyondspring Pharmaceuticals Inc Composicion y metodo para reducir la neutropenia.
WO2018144764A1 (en) * 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia

Also Published As

Publication number Publication date
AU2019216305A1 (en) 2020-08-27
WO2019152530A1 (en) 2019-08-08
KR20200116477A (ko) 2020-10-12
US20210030843A1 (en) 2021-02-04
JP2021512121A (ja) 2021-05-13
BR112020015758A2 (pt) 2020-12-08
NZ766454A (en) 2024-02-23
EP3746076A1 (en) 2020-12-09
RU2020126600A (ru) 2022-03-01
CA3089391A1 (en) 2019-08-08
CN112105363A (zh) 2020-12-18
EP3746076A4 (en) 2021-12-22
JP2024015120A (ja) 2024-02-01
IL276197A (en) 2020-09-30

Similar Documents

Publication Publication Date Title
IL276197A (en) Composition and method for reducing the neutrophil deficiency caused by chemotherapy through the administration of palinabolin and G-CSF factor
IL283840A (en) Preparations for administering therapeutic substances and methods for their use and preparation
IL283177A (en) Preparations and methods for delivering a specific charge to a cell
EP3813853A4 (en) DELIVERY COMPOSITIONS AND METHODS OF USE
IL276148A (en) A preparation and method for reducing platelet count through the administration of palinabolin
EP3946547A4 (en) DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS
EP3838265A4 (en) INJECTABLE PHARMACEUTICAL COMPOSITION AND METHOD FOR PREPARATION
EP4074334A4 (en) PHARMACEUTICAL COMPOSITION AND ITS USE
EP3773654C0 (en) POLYPHARMACEUTICAL DRUG COMPOSITIONS AND ASSOCIATED METHODS
EP3760191A4 (en) PHARMACEUTICAL COMPOSITION, PROCESS FOR PREPARATION AND USE OF THE LATTER
EP4048230C0 (en) ORAL GLIPTIN COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
EP3982942A4 (en) DRUG DELIVERY METHODS AND COMPOSITIONS
IL287137A (en) Preparations and methods for administration of healing substances
EP3485876A4 (en) ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING A PARTICULATE FORMULATION WITH THE COMPOSITION
EP3813842A4 (en) PHARMACEUTICAL COMPOSITION AND MANUFACTURING PROCESS THEREOF
EP3824888A4 (en) ORAL PHARMACEUTICAL COMPOSITION WITH FAB-I INHIBITORS AND PROCESS FOR THEIR MANUFACTURE
IL284132A (en) A pharmaceutical compound, a method for its preparation and its use as a medicinal substance
ZA202104261B (en) Combination pharmaceutical compositions and methods thereof
IL281080A (en) Preparations containing a compound containing selenite and a pharmaceutically acceptable acid for the treatment of human papillomavirus infection
IL281073A (en) History of imidazopyridine and pharmaceutical preparations containing them
EP3781194A4 (en) COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS
SG11202101547WA (en) Pharmaceutical composition for oral administration
EP3804722A4 (en) TREATMENT AGENT AND PHARMACEUTICAL COMPOSITION AGAINST GLIOMA
EP3790543A4 (en) COMPOSITIONS AND DOSAGE FORMS FOR ORAL ADMINISTRATION
EP3773732A4 (en) METHODS AND COMPOSITIONS FOR THE ADMINISTRATION OF A THERAPEUTIC AGENT